| Jonathan P. Mow |
Jonathan P. Mow founded Corus Pharma, Inc. He is Chief Executive Officer & Director at PhaseBio Pharmaceuticals, Inc.
In the past he occupied the position of Director-Worldwide Oncology Marketing at Bristol Myers Squibb Co. and Vice President-Business Development for Amylin Pharmaceuticals, Inc. (a subsidiary of Bristol Myers Squibb Co.), Principal at Syntex Laboratories, Inc., Principal at PathoGenesis Corp, Principal at Lederle International and Secretary & VP-Commercial & Business Development at Corus Pharma, Inc.
He received an undergraduate degree from the University of California, Berkeley and an MBA from Tepper School of Business. |
| Jonathan J. Birchall |
Jonathan J. Birchall is Chief Commercial Officer for PhaseBio Pharmaceuticals, Inc.
In his past career Mr. Birchall was Vice President & Head-US Thrombolytics Franchise at Genentech, Inc. |
| John S. Lee |
John S. Lee occupies the position of Chief Medical Officer for PhaseBio Pharmaceuticals, Inc.
Dr. Lee previously held the position of Medical Director at Merck & Co., Inc., Executive Director & Head-Cardiovascular at Bristol Myers Squibb Co. and Vice President for Quintiles Transnational Corp.
Dr. Lee received a doctorate from Boston University School of Medicine and an undergraduate degree from Harvard University. |
| Clay Bernardin Thorp |
Founder of 5 different companies, among them: PhaseBio Pharmaceuticals, Inc., Hatteras Venture Partners and Synthematix, Inc. Clay Bernardin Thorp and holds the position of Chairman for PhaseBio Pharmaceuticals, Inc. (which he founded in 2002), Director at GeneCentric Therapeutics, Inc. and General Partner of Hatteras Venture Partners (which he founded in 2000). Mr. Thorp is also on the board of 5 other companies.
He previously was Advisor at Research Triangle Ventures LLC, Chairman & Chief Executive Officer for Synthematix, Inc. (he founded the company), President for Xanthon, Inc. (he founded the company) and Director-Corporate Development at Karo Bio USA, Inc. (he founded the company).
Clay Bernardin Thorp received a graduate degree from Harvard University and an undergraduate degree from The University of North Carolina at Charlotte. |
| John P. Sharp |
Presently, John P. Sharp holds the position of Chief Financial Officer for PhaseBio Pharmaceuticals, Inc. and Chief Financial Officer & Vice President at Metabasis Therapeutics, Inc. He is also Member of The Association of Bioscience Financial Officers.
In his past career Mr. Sharp occupied the position of Chief Financial Officer & Vice President of Ligand Pharmaceuticals, Inc., Chief Financial Officer for HUYA Bioscience International LLC, Chief Accounting Officer & Vice President at Sequenom, Inc., Accounting Director at Diversa Corp. and Senior Audit Manager at PricewaterhouseCoopers LLP.
Mr. Sharp received an undergraduate degree from San Diego State University. |
| Alex C. Sapir |
Currently, Alex C. Sapir occupies the position of Chief Executive Officer & Director at ReViral Ltd. He is also on the board of PhaseBio Pharmaceuticals, Inc.
In his past career he held the position of Executive Vice President-Marketing & Sales at United Therapeutics Corp., Director at Dova Pharmaceuticals, Inc. and Senior Director-Marketing at Guilford Pharmaceuticals, Inc.
Alex C. Sapir received an MBA from Harvard Business School and an undergraduate degree from Franklin & Marshall College. |
| Caroline M. Loewy |
Caroline M. Loewy founded Achieve Life Sciences, Inc. She is on the board of CymaBay Therapeutics, Inc. and 4 other companies.
In the past Ms. Loewy occupied the position of Chief Financial Officer at Poniard Pharmaceuticals, Inc., Chief Financial Officer for Corcept Therapeutics, Inc., Chief Financial & Business Officer at Achieve Life Sciences, Inc., Chief Financial Officer for Tobira Therapeutics, Inc., Managing Director-Biotechnology Equity Research at Prudential Securities and Research Analyst at Morgan Stanley & Co. LLC.
Ms. Loewy received a graduate degree and an MBA from Carnegie Mellon University and an undergraduate degree from the University of California, Berkeley. |
| Richard van den Broek |
Richard van den Broek founded HSMR Advisors LLC. Currently, he is Managing Partner at this company. He is also on the board of PhaseBio Pharmaceuticals, Inc., Cogstate Ltd. and Pulse Biosciences, Inc.
In his past career he held the position of Partner at Cooper Hill Partners LLC and Biotech Analyst at Oppenheimer & Co., Inc.
He received an undergraduate degree from Harvard University. |
| Nancy J. Hutson |
Nancy J. Hutson is Owner at Ledyard Co. and on the board of 8 other companies.
In her past career she was Senior VP-Global Research & Development at Pfizer Inc.
Dr. Hutson received an undergraduate degree from Illinois Wesleyan University and a doctorate from Vanderbilt University. |
| William D. Humphries |
William D. Humphries is a businessperson who has been at the head of 11 different companies and presently holds the position of Chairman for STRATA Skin Sciences, Inc., Chairman at Clearside Biomedical, Inc., Chairman for Merz LLC, Chief Executive Officer of Isosceles Pharmaceuticals, Inc., Chairman for Merz Pharmaceuticals LLC and Chief Executive Officer & Director at Onpharma, Inc. Mr. Humphries is also on the board of PhaseBio Pharmaceuticals, Inc., Aclaris Therapeutics, Inc. and Merz Pharma Canada Ltd. and Chairman-Global Luxury Management Board at North Carolina State University.
William D. Humphries previously occupied the position of President-Ortho Dermatologics at Bausch Health Cos., Inc. Group Chairman & Executive Vice President at OraPharma, Inc. and President & Director at Medicis Pharmaceutical Corp. (both are subsidiaries of Bausch Health Cos., Inc.), Chairman, President & Chief Executive Officer at Merz, Inc., President & Chief Executive Officer of Merz North America, Inc., President-Dermatology at Stiefel Laboratories, Inc. and Vice President-Sales & Marketing for Allergan, Inc.
He received an MBA from Pepperdine University and an undergraduate degree from Bucknell University. |
| Edmund P. Harrigan |
Edmund P. Harrigan is on the board of Incyte Corp., ACADIA Pharmaceuticals, Inc., PhaseBio Pharmaceuticals, Inc. and AlgoTherapeutix SAS. In the past Dr. Harrigan occupied the position of Senior VP-Worldwide Safety & Regulatory at Pfizer Inc.
Dr. Harrigan received an undergraduate degree from St. Anselm College and a doctorate from the University of Massachusetts Medical School. |
